Nasopharyngeal carcinoma (NPC) is poorly differentiated and thus is highly malignant, which is prone to distal metastasis as compared with other head and neck tumors [1,2] . A study from Radiation Therapy Oncology Group (RTOG) showed that carcinomas from the lower laryngeal and nasopharyngeal regions had much higher prevalence of micrometastasis at initial diagnosis [3] . Thanks to the use of threedimensional conformal radiotherapy and intensity modulated conformal therapy, the regional control rate of NPC has been markedly improved, and the recurrence rates of NPC and regional lymph nodes have been decreased. As a result, the issue of treatment failure owing to distal metastasis became prominent; about 15%19% of the patients with NPC had a treatment failure due to distal metastasis [1,46] . The lung is the most commonly affected organ, and lung 787
窑Original Article窑 Nasopharyngeal carcinoma (NPC) is poorly differentiated and thus is highly malignant, which is prone to distal metastasis as compared with other head and neck tumors [1, 2] . A study from Radiation Therapy Oncology Group (RTOG) showed that carcinomas from the lower laryngeal and nasopharyngeal regions had much higher prevalence of micrometastasis at initial diagnosis [3] . Thanks to the use of threedimensional conformal radiotherapy and intensity modulated conformal therapy, the regional control rate of NPC has been markedly improved, and the recurrence rates of NPC and regional lymph nodes have been decreased. As a result, the issue of treatment failure owing to distal metastasis became prominent; about 15%19% of the patients with NPC had a treatment failure due to distal metastasis [1, 46] . The lung is the most commonly affected organ, and lung metastasis is one the main causes of treatment failure. Some studies show that some patients with metastasis from NPC may have a good prognosis if comprehensive treatment is used [7, 8] . The patients with lung metastasis from NPC have significantly longer progressionfree and overall survival than those with other organs involved [5] . The solitary metastatic lung tumor is a distinct metastatic pattern that has particular biological features. It carries better prognosis after treatment. The survival of these patients could be prolonged or the tumor can be cured if treated appropriately. However, there is no consensus on the treatment of such tumor. Chemotherapy, radiotherapy, and operation are the mainstay treatment modalities. Currently, the response rate of solitary metastatic lung tumor from NPC ranges 45% 60% [911] . Chemotherapy plays an important role in some of the patients. The development of novel drugs and the use of combination chemotherapy and maintenance chemotherapy in recent years all contribute to the increasing response rate of the disease. However, the overall treatment efficacy is suboptimal. Radiotherapy remains the mainstay treatment of NPC, and is also widely used to treat the metastatic lung tumor from NPC. A study proposed that the local small field radiation was effective for the patients with solitary metastatic lung tumor but without local recurrence [9] . Some other novel techniques such as directional radiotherapy makes the therapy more accurate and less invasive. Many evidences have proven that operation as a palliative strategy can provide longterm survival to the patients [12] . The widely accepted prognostic factor is the thoroughness of resection. Lung wedge resection and segmental resection are the most commonly used procedures, and have some priorities in the treatment of solitary metastatic lung tumor from NPC. Chemotherapy, radiotherapy, and operation have their merits and limitations in the treatment of solitary metastatic lung tumor from NPC. Chemotherapy alone, radiotherapy or radiochemotherapy, operation or operation plus chemotherapy are usually used. There are few studies comparing the effects of these modalities. The present study reviewed clinical data of 105 patients with metastatic lung tumor from NPC, compared the efficacies of different modalities, and investigated the most appropriate therapeutic modality and the prognostic factors.
Clinical data of 105 patients with solitary metastatic lung tumor from NPC treated in Sun Yatsen University Cancer Center between September 1994 and September 2008 were reviewed. Of them, 89 were initially treated in our center, 16 were diagnosed in other hospitals and then referred to our hospital. The time of initial diagnosis of NPC ranged from April 1977 to July 2008.
Inclusion criteria: (1) Patients with pathologically confirmed NPC; (2) The metastatic lung tumor was determined by chest Xray or chest CT; (3) Metastasis to other organs were excluded by Bmode ultrasound and bone ECT scan; (4) Performancestatus score during treatment ranged from 0 to 1; (5) The therapeutic evaluation of primary lesion and regional lymph nodes was determined to be complete remission (CR) or partial remission (PR); (6) The metastatic lung tumor was treated in our hospital and the complete clinical data were available. Radical radiotherapy was performed for the primary tumor in all patients. The accumulative radiation dose was 6478 Gy for primary lesion and 5074 Gy for regional lymph nodes. Adjunctive chemotherapeutic sensitizations were performed in 60 patients, using cisplatin (DDP) alone or in combination with 5fluorouracil (5FU) (PF regimen). Therapeutic efficacy was assessed 3 months after initial treatment, showing 99 cases of CR and 6 cases of PR for primary tumor, and 94 cases of CR and 11 cases of PR for regional lymph nodes.
Of the 105 patients confirmed to have solitary metastatic lung tumor, 52 underwent systemic chemotherapy; 1 underwent radiotherapy alone, 24 underwent chemotherapy + radiotherapy; 13 underwent operation alone and 15 underwent operation + adjunctive chemotherapy. Platinumbased regimens were used for chemotherapy, including PF, PBF (DDP+BLM+5FU), and GP (GEM+DDP) regimens. Twentytwo patients underwent local small field radiation (total dose, 5068 Gy), 3 underwent total lung radiation (2024 Gy) + local small field www.cjcsysu.cn complementary radiation (5062 Gy). Twentysix patients underwent single operation, 1 underwent a second operation due to recurrent lung tumor, and 1 underwent a third operation; 20 cases of lung wedge resection and lung segmental resection, and 11 cases of lobectomy were performed. Eight cases of lymph node dissection or sampling were performed, and the postoperative pathology showed 3 cases of mediastinal lymph node metastases and 5 cases free of metastasis.
According to the treatment modalities, the patients were divided into chemotherapy alone group, radiotherapy +/ chemotherapy group, and operation +/ chemotherapy group. The shortterm and longterm efficacy of different treatment modalities were evaluated. The shortterm efficacy, based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria, were assessed as CR, PR, stable disease (SD), progressive disease (PD), and no assessment (NA); CR and PR were regarded as treatment responses. The efficacy was assessed at 2 weeks after chemotherapy, 3 months after radiotherapy, and 1 month after operation.
The patients were followed up till January 31, 2010. The longterm efficacy was evaluated according to the progressionfree survival (PFS) and overall survival (OS). OS was calculated from the first day at the completion of treatment to death or to the end of followup, and PFS was calculated from the completion of treatment to the disease progression (newly occurred metastatic lesion, recurrence or expansion of the primary lesion). Diseasefree interval (DFI) was calculated from the completion of initial treatment to the time when the lung lesion was identified.
The hilar/mediastinal lymph node involvement was defined when the imaging showed lymph nodes >1 cm in diameter or the dissected specimen was pathologically positive. Univariate and multivariate analyses for patients爷 survival were performed by incorporating factors such as gender, age (< 45, 逸45), pathologic type, stage of NPC, initial use of adjunctive chemotherapy, treatment evaluation of NPC, DFI, the size of metastatic lung tumor, the involvement of hilar or mediastinal lymph nodes after lung metastasis, treatment of metastatic lung tumor, recurrence and distal metastasis.
Statistical analysis was performed using SPSS 13.0 package. The relationship between different treatment modalities and clinicopathologic factors was analyzed using the Chisquare test. Data of shortterm efficacy were tested for homogeneity of variance. OneWay ANOVA and LSDt tests were performed if the variance was homogeneous, otherwise, the Tamhane爷s T2 test was performed. OS rates were calculated using the KaplanMeier method and compared by the logrank test. Statistical significance was defined when < 0.05 by the twotailed test. Multivariate analysis was performed using Cox proportional hazard regression model.
No death or severe complications were reported during treatment. All 105 patients were followed up with complete data available ( Table 1 ). The median followup was 68.3 months (range: 7330 months). The median DFI was 29.6 months (0273 months).
Shortterm efficacy was assessable in 103 patients (Table 2 ); 2 were not assessed because they hadn爷t undergone chest CT scan in due time. The local control rate was significantly lower in chemotherapy group than radiotherapy +/ chemotherapy group and operation +/ chemotherapy group (53.8% vs. 88.0% and 96.4% , < 0.01).
The OS rates, PFS and OS are shown in Table 3 . Operation +/ chemotherapy prolonged the PFS and OS, and radiotherapy +/ chemotherapy also improved survival rate. Both modalities were superior to chemotherapy ( < 0.001) ( Table 4) . Figures 1 and 2 demonstrate the PFS and OS curves of the patients under different treatment modalities.
Cox proportional hazard regression analyses showed that recurrent distal metastasis or local recurrence affected the prognosis of solitary metastatic lung tumor from NPC (OR = 2.087, 95% CI = 1.2773.410, = 0.003). Fiftyone (48.6%) patients had recurrent distal metastasis: 21 (20.0% ) had lung metastasis, 9 (8.6% ) had bone metastasis, 7 (6.7% ) had liver metastasis, 3 (2.9% ) had other sites involved, and 11 (10.5% ) had multiple metastases. After treatment for metastatic lung tumor from NPC, 8 (7.6% ) patients had nasopharyngeal recurrence, 2 (1.9% ) had regional lymph node recurrence. Moreover, the size of metastatic tumor, status of hilar/mediastinal lymph nodes, T stage of NPC, and treatment modality all related with the survival (Table 5) .
NPC is common in China. The lungs are the most common site of metastasis, and no consensus exists for its treatment. The present study retrospectively reviewed clinical data of the patients with solitary metastatic lung tumor from NPC, and compared the short and longterm efficacies of chemotherapy, radiotherapy +/ chemotherapy, and operation +/ chemotherapy. Our results showed that operation +/ chemotherapy was superior to the other two modalities ( < 0.01), which improved the local control rate, prolonged the PFS and OS. Moreover, radiotherapy +/ chemotherapy was also superior to chemotherapy alone ( < 0.001).
Currently, operation is rarely used to treat metastatic lung tumor from NPC. Cheng . [13] reported that the 12 patients treated by surgical resection of solitary metastatic www.cjcsysu.cn lung tumor plus adjunctive chemotherapy had higher 2year survival rate than the 65 patients treated by chemotherapy alone (80.0% vs. 24.1% , < 0.001). These results are consistent with ours. For the patients with solitary metastatic lung tumor from NPC, operation is recommended if there is no contraindication. Operation shows some priorities. First, the excised specimen is sent for immunohistochemical assay and compared with the primary lesions, which can help to exclude the potential primary lung cancer that has different treatment modalities [14, 15] . The patients who undergo chemotherapy and/or radiotherapy are determined to have metastatic lung tumor based on medical history, imaging, and EpsteinBarr virus (EBV)related antibody titers, and thus risk the likelihood of misdiagnosis. Second, surgical resection of the metastatic lung tumor features in completeness of resection, minimal invasiveness, rapid recovery, and short treatment course. In contrast, radiotherapy, despite of its high accuracy of localization, may be uncertain in the therapeutic effect. The shortterm efficacy of operation is optimal. Third, in addition to the tumor resection, the remaining pulmonary lobes can be examined by palpation during operation to identify some potential nodules that are not demonstrated in imaging. Forth, suspected lymph nodes can be dissected during operation to evaluate the lymph node status. The patients with lymph node metastasis should undergo lymph node dissection and postoperative comprehensive treatment.
The patients who have unresectable tumors, contraindicate to operation, or are unwilling to receive operation could be recommended to have radiotherapy +/ chemotherapy. The metastatic lung tumor from NPC is sensitive to radiotherapy. Yi . [9] treated 60 patients with metastatic lung tumor from NPC by different modalities, and found that the effective rate of radiotherapy was 88.0%, and that the radiotherapy +/ chemotherapy (32 cases) was more effective than chemotherapy alone (9 cases) ( = 0.001). In our study, 25 patients underwent radiotherapy +/ chemotherapy, and the 1, 3 and 5year survival rates were 96.0%, 56.0% and 24.0%, respectively, the median survival time was 49.6 months. The effective rate of radiotherapy was 88.0%, and its shortterm efficacy and its benefit to the PFS and OS were superior to chemotherapy alone. Xray stereotactic radiotherapy (SRT) is developed in recent years and is a treatment option of metastatic lung tumor because its radiation energy can be accurately targeted to the lesion with little injury to the neighboring normal tissues, and it is not restricted by the sensitivity of the tumor tissue . In addition, the use of SRT is not restricted by the patients爷 general condition. It is less invasive with little injury to the body, and is suitable to patients with surgical contraindications. Wu .
[16]
observed 39 cases of metastatic lung tumor treated, including 12 from NPC, with SRT. The shortterm efficacy was 88.0% , and the 2year OS rate of the patients with solitary metastatic lung tumor was 57.7%. However, the number of patients with metastatic lung tumor from NPC treated with SRT is small, and most of them have small tumors. The longterm efficacy mandates further investigations.
Both operation and radiotherapy are local treatments, and do not affect the biological behaviors and metastatic nature of the tumor. For advanced NPC, the treatment should target its biological behaviors, that is, comprehensive modalities, including chemotherapy, biological target therapy, and genotherapy, can be used to eliminate the micrometastatic lesions, thereby prevent the spread of the tumor. Currently, chemotherapy is the most widely used Local control* *Local control was evaluated by RECIST criteria 1.0: CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; NA, not assessable. Among our patients with solitary metastatic lung tumor from NPC, 48.6% had recurrent metastasis after treatment, mostly in the lungs, bone, and liver. Thus, chemotherapy as a systemic treatment is very important. Chemotherapy has the synergistic effect with operation and radiotherapy by acting on different targets. Moreover, chemotherapy can arrest the tumor cells in the radiotherapysensitive phase, thereby improving the local control rate and OS of patients treated by radiotherapy. However, in our study, the efficacy of chemotherapy alone was worse than the other two modalities. It is probably that the metastatic lung tumors from NPC are poorly differentiated or undifferentiated squamous carcinoma, and thus is moderately sensitive to chemotherapy. Leong . [18] has demonstrated that maintenance regimen with 5FU and folinic acid following the triple regimen of gemcitabine, paclitaxel and carboplatin had certain effect on distal metastasis from NPC. To further improve the efficacy of chemotherapy on metastatic lung tumor from NPC, novel drugs or regimens with a high sensitivity are urgently needed.
In addition, the Cox proportional hazard regression model revealed that the recurrence of distal metastasis and primary tumor are major prognostic factors (OR = 2.087, = 0.003). The size of metastatic tumor, status of hilar/mediastinal lymph nodes, T stage of NPC, and the therapeutic modality were independent prognostic factors of the metastatic lung tumor from NPC. For patients with high risk factors, such as advanced T stage, a diameter of the tumor of 逸 3 cm, and positive mediastinal lymph nodes, adjunctive chemotherapy is recommended, which may be beneficial to the prognosis.
Conclusively, operation +/ chemotherapy and radiotherapy +/ chemotherapy are effective for the solitary metastatic lung tumor from NPC in improving the local control rate, prolonging PFS and OS. Operationbased comprehensive therapy is recommended for the patients with solitary metastatic lung tumor from NPC but without other organs involved or surgical contraindications. Otherwise, radiotherapy +/ chemotherapy is the option for those with unresectable tumor, contraindications to operation, or are reluctant to have operation. Adjunctive systemic chemotherapy is indicated for patients with advanced T stage, diameters of the metastatic lung tumor of 逸 3 cm, or positive hilar/mediastinal lymph nodes. Due to the retrospective nature of the present study, the results need to be confirmed by multicenter, randomized, controlled trials. Metastatic lung tumor from NPC is an advanced disease. The aim of future studies is to develop an individualized modality for each patient, thereby relieving clinical symptoms, improving the quality of life and prolonging patients爷 survival. 
